Ads
related to: panitumumab package insert
Search results
Results From The WOW.Com Content Network
Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS". Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.
DailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care providers and the general public.
A package insert from 1970, with Ovrette brand contraception pills. A package insert is a document included in the package of a medication that provides information about that drug and its use. For prescription medications, the insert is technical, providing information for medical professionals about how to prescribe the
[4] [5] The most common adverse reactions for sotorasib used in combination with panitumumab include rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal pain. [ 4 ] [ 9 ] Sotorasib is the first approved targeted therapy for people with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small ...
Fannie and Freddie, which buy mortgages and package them into bonds to sell to investors, are a crucial source of liquidity for the mortgage market and allow lenders to keep making new loans.
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2]
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). [2] [3] [4] It belongs to the tyrosine kinase inhibitor family of medications. [5]